October 2019 Volume 15, Issue 10

Volume 15, Issue 10 | October 2019
October 2019
In this Issue
Feature

Focus Feature on CRISPR Gene Editing: What’s new with CRISPR?
A roundup of recent news and breakthroughs with the gene-editing technology
AMP 2019 Show Preview: Marking a quarter-century of molecular pathology
Association for Molecular Pathology brings its annual meeting and expo to BaltimoreDiscovery

Going GENTRL
Insilico Medicine has validated its new GENTRL AI system
Getting to grips with chemoresistance
Scientists develop drug-resistant cell line for lymphoma to better model disease development and drug reactions
A path to prevent addiction?
Scripps Research finds an anti-opioid pathway
AI answers
Atomwise collaborates for drug developmentDiagnostics

AI-based blood testing
Diagnostics detect cancer in dense breasts
T2 keeps trucking along
Company’s direct-from-blood diagnostic tests post strong data, supporting multiple distribution agreements
A focus on FFPE
Pressure BioSciences’ PCT platform lauded for its ability to process cancer biopsy samples
What’s the hubbub?
NUS, Agilent and NUH launch new translational R&D hub to boost clinical diagnostics
Scientists create a faster DNA testing method
New ‘Vilnius-made’ method reportedly reduces DNA testing costs by 90 percentResearch & Development

Pinpointing patients
Researchers identify immune biomarker showing which HCC patients would benefit most from sorafenib
Brain vs. brain
Brain organoids and brains of premature babies generate similar EEG patterns
Gut check
French biotech company raises €6.2M for gut microbiome R&D
Teaming up on autoimmune disease
Exagen and University of Washington collaborate on lupus and rheumatoid arthritis research
Pushing against cancer
Crescendo to collaborate with University of Oxford and University of SurreySpecial Reports

Special Report on Cell Biology: Making bioprogress
Expanding bioprocess analytics to ensure qualityEditor's Focus

Editor’s Focus: An embarrassment of riches
From a Focus Feature to Q&As, there's no shortage of bonus pieces in our October issue; no matter which indications interest you most, there's something for everyoneContract Services

Making moves
Sygnature Discovery moves U.S. base to Kendall SquareBusiness & Government Policy

New campaign focuses on fighting superbugs
Working to Fight AMR aims to spur development of new antibiotics
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Not passing the finish line
Many pre-approved prescription drugs have not completed FDA approval process
Cannabidiol vs. epilepsy
NICE to work with GW Pharma on appraisals of cannabidiolClinical Trials

Battling Batten disease
Amicus gene therapy brings in positive interim results
Safety and statistical significance
Patients respond well to Aclaris’ ATI-501 in alopecia areata trial
An influx of focus on wet AMD
A trio of companies report trial progression or positive data for AMD-targeted therapeuticsPreclinical

Positive results for radiation prophylaxis
Pluristem and the Department of Defense present positive PLX-R18 data
Healthy data for Cytokinetics' HCM candidate
CK-274, which addresses hypercontractility in hypertrophic cardiomyopathy, reduces contractility in preclinical models
Rodents to the rescue
Taconic and ContraVir report positive preclinical tests for treating NASHCommentary

Optimized dosing: We can do better, but when?
While we are increasingly able to make better drug choices for subpopulations thanks to companion diagnostics and more, actually optimizing dosing for an individual is an aspirational goal right now
Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models
An understanding of the patent history and intellectual property landscape surrounding the use of the CRISPR/Cas9 system is critical for any researcher considering designing a mouse or rat model using this technology

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe